Cargando…
Exosome engineering in cell therapy and drug delivery
Cell-derived exosomes have opened new horizons in modern therapy for advanced drug delivery and therapeutic applications, due to their key features such as low immunogenicity, high physicochemical stability, capacity to penetrate into tissues, and the innate capacity to communicate with other cells...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823267/ https://www.ncbi.nlm.nih.gov/pubmed/36609717 http://dx.doi.org/10.1007/s10787-022-01115-7 |
_version_ | 1784866118439010304 |
---|---|
author | Sadeghi, Somaye Tehrani, Fahimeh Ramezani Tahmasebi, Safa Shafiee, Abbas Hashemi, Seyed Mahmoud |
author_facet | Sadeghi, Somaye Tehrani, Fahimeh Ramezani Tahmasebi, Safa Shafiee, Abbas Hashemi, Seyed Mahmoud |
author_sort | Sadeghi, Somaye |
collection | PubMed |
description | Cell-derived exosomes have opened new horizons in modern therapy for advanced drug delivery and therapeutic applications, due to their key features such as low immunogenicity, high physicochemical stability, capacity to penetrate into tissues, and the innate capacity to communicate with other cells over long distances. Exosome-based liquid biopsy has been potentially used for the diagnosis and prognosis of a range of disorders. Exosomes deliver therapeutic agents, including immunological modulators, therapeutic drugs, and antisense oligonucleotides to certain targets, and can be used as vaccines, though their clinical application is still far from reality. Producing exosomes on a large-scale is restricted to their low circulation lifetime, weak targeting capacity, and inappropriate controls, which need to be refined before being implemented in practice. Several bioengineering methods have been used for refining therapeutic applications of exosomes and promoting their effectiveness, on the one hand, and addressing the existing challenges, on the other. In the short run, new diagnostic platforms and emerging therapeutic strategies will further develop exosome engineering and therapeutic potential. This requires a thorough analysis of exosome engineering approaches along with their merits and drawbacks, as outlined in this paper. The present study is a comprehensive review of novel techniques for exosome development in terms of circulation time in the body, targeting capacity, and higher drug loading/delivery efficacies. |
format | Online Article Text |
id | pubmed-9823267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98232672023-01-09 Exosome engineering in cell therapy and drug delivery Sadeghi, Somaye Tehrani, Fahimeh Ramezani Tahmasebi, Safa Shafiee, Abbas Hashemi, Seyed Mahmoud Inflammopharmacology Review Cell-derived exosomes have opened new horizons in modern therapy for advanced drug delivery and therapeutic applications, due to their key features such as low immunogenicity, high physicochemical stability, capacity to penetrate into tissues, and the innate capacity to communicate with other cells over long distances. Exosome-based liquid biopsy has been potentially used for the diagnosis and prognosis of a range of disorders. Exosomes deliver therapeutic agents, including immunological modulators, therapeutic drugs, and antisense oligonucleotides to certain targets, and can be used as vaccines, though their clinical application is still far from reality. Producing exosomes on a large-scale is restricted to their low circulation lifetime, weak targeting capacity, and inappropriate controls, which need to be refined before being implemented in practice. Several bioengineering methods have been used for refining therapeutic applications of exosomes and promoting their effectiveness, on the one hand, and addressing the existing challenges, on the other. In the short run, new diagnostic platforms and emerging therapeutic strategies will further develop exosome engineering and therapeutic potential. This requires a thorough analysis of exosome engineering approaches along with their merits and drawbacks, as outlined in this paper. The present study is a comprehensive review of novel techniques for exosome development in terms of circulation time in the body, targeting capacity, and higher drug loading/delivery efficacies. Springer International Publishing 2023-01-07 2023 /pmc/articles/PMC9823267/ /pubmed/36609717 http://dx.doi.org/10.1007/s10787-022-01115-7 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Sadeghi, Somaye Tehrani, Fahimeh Ramezani Tahmasebi, Safa Shafiee, Abbas Hashemi, Seyed Mahmoud Exosome engineering in cell therapy and drug delivery |
title | Exosome engineering in cell therapy and drug delivery |
title_full | Exosome engineering in cell therapy and drug delivery |
title_fullStr | Exosome engineering in cell therapy and drug delivery |
title_full_unstemmed | Exosome engineering in cell therapy and drug delivery |
title_short | Exosome engineering in cell therapy and drug delivery |
title_sort | exosome engineering in cell therapy and drug delivery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823267/ https://www.ncbi.nlm.nih.gov/pubmed/36609717 http://dx.doi.org/10.1007/s10787-022-01115-7 |
work_keys_str_mv | AT sadeghisomaye exosomeengineeringincelltherapyanddrugdelivery AT tehranifahimehramezani exosomeengineeringincelltherapyanddrugdelivery AT tahmasebisafa exosomeengineeringincelltherapyanddrugdelivery AT shafieeabbas exosomeengineeringincelltherapyanddrugdelivery AT hashemiseyedmahmoud exosomeengineeringincelltherapyanddrugdelivery |